Nyxoah (NASDAQ:NYXH) Stock Price Target Lowered at Cantor Fitzgerald

Nyxoah (NASDAQ:NYXH – Get Free Report) had its price objective reduced by investment analysts at Cantor Fitzgerald to $3.00 in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target would suggest a potential upside of 230.76% from the company’s current price.

A number of other brokerages have also recently commented on NYXH. Wall Street Zen cut shares of Nyxoah from a “hold” rating to a “sell” rating in a report on Sunday, August 9th. Oppenheimer set a $4.00 price objective on shares of Nyxoah in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Nyxoah in a research note on Wednesday, August 19th. Robert W. Baird set a $2.31 target price on Nyxoah in a report on Thursday, August 6th. Finally, Piper Sandler reissued an “overweight” rating and set a $6.00 price target (down from $7.00) on shares of Nyxoah in a report on Thursday, August 6th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.55.

Check Out Our Latest Analysis on Nyxoah

Nyxoah Stock Performance

NASDAQ:NYXH traded up $0.01 on Tuesday, hitting $0.91. The stock had a trading volume of 74,820 shares, compared to its average volume of 207,207. The business’s 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $2.56. The stock has a market cap of $35.16 million, a price-to-earnings ratio of -0.36 and a beta of 1.65. Nyxoah has a 52-week low of $0.80 and a 52-week high of $5.92. The company has a quick ratio of 2.31, a current ratio of 2.38 and a debt-to-equity ratio of 0.44.

Nyxoah (NASDAQ:NYXH – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The business had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. As a group, research analysts predict that Nyxoah will post -1.44 earnings per share for the current year.

Institutional Trading of Nyxoah

Several institutional investors and hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new position in Nyxoah in the 2nd quarter worth $169,000. IFP Advisors Inc raised its holdings in Nyxoah by 35.6% during the second quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after acquiring an additional 31,061 shares during the period. Finally, Readystate Asset Management LP purchased a new position in shares of Nyxoah in the second quarter valued at about $351,000.

About Nyxoah

(Get Free Report)

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.

Featured Articles

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.